Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas

Lorenzo Manconi, Elisa Coviello, Filippo Canale, Livia Giannoni, Paola Minetto, Fabio Guolo, Marino Clavio, Riccardo Marcolin, Michele Cea, Antonia Cagnetta, Marco Gobbi, Maurizio Miglino, Filippo Ballerini, Roberto Massimo Lemoli

Research output: Contribution to journalArticle

Abstract

Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B cell lymphomas (DLBCL) treated in our center (median lines 2, range 2-5; median age 59, range 22–79). Hematological toxicity was manageable and no patients experienced renal impairment. After 2 courses the overall response rate was 60% (CR 49%, PR 11%). Median overall survival (OS) was 30.53 months (95% CI 11.5–49.55), 3-year OS 40.5%. Twenty-two eligible patients collected HSC and transplantation was performed in 21/22 patients (95%), after a median of 52 days from last cycle. Our results suggest that in DLBCL R-DHAOx has an excellent stem cell mobilizing capability, response rate comparable to cisplatin-containing regimens and good toxicity profile.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

oxaliplatin
Lymphoma, Large B-Cell, Diffuse
Cytarabine
Cell- and Tissue-Based Therapy
Dexamethasone
Stem Cells
Hematopoietic Stem Cell Transplantation
Cisplatin
Survival
Standard of Care
Lymphoma
Kidney

Keywords

  • Oxaliplatin
  • refractory/relapsed diffuse large B cell lymphoma
  • salvage
  • stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. / Manconi, Lorenzo; Coviello, Elisa; Canale, Filippo; Giannoni, Livia; Minetto, Paola; Guolo, Fabio; Clavio, Marino; Marcolin, Riccardo; Cea, Michele; Cagnetta, Antonia; Gobbi, Marco; Miglino, Maurizio; Ballerini, Filippo; Lemoli, Roberto Massimo.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

@article{0b46169751f64f599c7f8e19c6cd769e,
title = "Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas",
abstract = "Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B cell lymphomas (DLBCL) treated in our center (median lines 2, range 2-5; median age 59, range 22–79). Hematological toxicity was manageable and no patients experienced renal impairment. After 2 courses the overall response rate was 60{\%} (CR 49{\%}, PR 11{\%}). Median overall survival (OS) was 30.53 months (95{\%} CI 11.5–49.55), 3-year OS 40.5{\%}. Twenty-two eligible patients collected HSC and transplantation was performed in 21/22 patients (95{\%}), after a median of 52 days from last cycle. Our results suggest that in DLBCL R-DHAOx has an excellent stem cell mobilizing capability, response rate comparable to cisplatin-containing regimens and good toxicity profile.",
keywords = "Oxaliplatin, refractory/relapsed diffuse large B cell lymphoma, salvage, stem cell mobilization",
author = "Lorenzo Manconi and Elisa Coviello and Filippo Canale and Livia Giannoni and Paola Minetto and Fabio Guolo and Marino Clavio and Riccardo Marcolin and Michele Cea and Antonia Cagnetta and Marco Gobbi and Maurizio Miglino and Filippo Ballerini and Lemoli, {Roberto Massimo}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1658102",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas

AU - Manconi, Lorenzo

AU - Coviello, Elisa

AU - Canale, Filippo

AU - Giannoni, Livia

AU - Minetto, Paola

AU - Guolo, Fabio

AU - Clavio, Marino

AU - Marcolin, Riccardo

AU - Cea, Michele

AU - Cagnetta, Antonia

AU - Gobbi, Marco

AU - Miglino, Maurizio

AU - Ballerini, Filippo

AU - Lemoli, Roberto Massimo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B cell lymphomas (DLBCL) treated in our center (median lines 2, range 2-5; median age 59, range 22–79). Hematological toxicity was manageable and no patients experienced renal impairment. After 2 courses the overall response rate was 60% (CR 49%, PR 11%). Median overall survival (OS) was 30.53 months (95% CI 11.5–49.55), 3-year OS 40.5%. Twenty-two eligible patients collected HSC and transplantation was performed in 21/22 patients (95%), after a median of 52 days from last cycle. Our results suggest that in DLBCL R-DHAOx has an excellent stem cell mobilizing capability, response rate comparable to cisplatin-containing regimens and good toxicity profile.

AB - Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell (HSC) transplantation are the current standard of care for relapsed or refractory (R/R) lymphomas. We retrospectively analyzed efficacy and stem cell mobilizing activity of oxaliplatin, cytarabine, dexamethasone and rituximab (R-DHAOx) in 53 R/R diffuse large B cell lymphomas (DLBCL) treated in our center (median lines 2, range 2-5; median age 59, range 22–79). Hematological toxicity was manageable and no patients experienced renal impairment. After 2 courses the overall response rate was 60% (CR 49%, PR 11%). Median overall survival (OS) was 30.53 months (95% CI 11.5–49.55), 3-year OS 40.5%. Twenty-two eligible patients collected HSC and transplantation was performed in 21/22 patients (95%), after a median of 52 days from last cycle. Our results suggest that in DLBCL R-DHAOx has an excellent stem cell mobilizing capability, response rate comparable to cisplatin-containing regimens and good toxicity profile.

KW - Oxaliplatin

KW - refractory/relapsed diffuse large B cell lymphoma

KW - salvage

KW - stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=85071963994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071963994&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1658102

DO - 10.1080/10428194.2019.1658102

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -